Author

Antonio Gasbarrini

POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY
POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY

Antonio Gasbarrini  et al.

Faecal microbiota transplantation
Faecal microbiota transplantation

Antonio Gasbarrini  et al.

REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY
REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY

Antonio Gasbarrini  et al.

IL-33 ACTIVATES CD73-EXPRESSING CELLS PROMOTING TUMORIGENESIS DURING COLITIS-ASSOCIATED COLORECTAL CANCER
IL-33 ACTIVATES CD73-EXPRESSING CELLS PROMOTING TUMORIGENESIS DURING COLITIS-ASSOCIATED COLORECTAL CANCER

Antonio Gasbarrini  et al.

IPMN PROGRESSION OVER TIME: THE ROLE OF LIFESTYLE AND MEDICATIONS
IPMN PROGRESSION OVER TIME: THE ROLE OF LIFESTYLE AND MEDICATIONS

Antonio Gasbarrini  et al.

LONG TERM FOLLOW-UP OF CHRONIC LIVER DISEASE IN WILSON PATIENTS: THE ROLE OF NON INVASIVE TESTS
LONG TERM FOLLOW-UP OF CHRONIC LIVER DISEASE IN WILSON PATIENTS: THE ROLE OF NON INVASIVE TESTS

Antonio Gasbarrini  et al.

ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Antonio Gasbarrini  et al.

EARLY METABOLIC EVALUATION OF RESPONSE BY 13N-AMMONIA PET-CT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH ANTIANGIOGENIC THERAPY
EARLY METABOLIC EVALUATION OF RESPONSE BY 13N-AMMONIA PET-CT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH ANTIANGIOGENIC THERAPY

Antonio Gasbarrini  et al.

HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS
HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS

Antonio Gasbarrini  et al.

INTERROGATION OF DIET-INDUCED CHANGES IN THE MICROBIOME USING METAPROTEOMIC ANALYSIS OF CROHN’S DISEASE PATIENTS RECEIVING A CATERED HIGH FIBER, LOW FAT DIET INTERVENTION
INTERROGATION OF DIET-INDUCED CHANGES IN THE MICROBIOME USING METAPROTEOMIC ANALYSIS OF CROHN’S DISEASE PATIENTS RECEIVING A CATERED HIGH FIBER, LOW FAT DIET INTERVENTION

Antonio Gasbarrini  et al.

CHARACTERIZATION OF MUCOSAL CYTOKINE PROFILE IN ULCERATIVE COLITIS PATIENTS UNDER CONVENTIONAL AND ANTI-TNF-A TREATMENT
CHARACTERIZATION OF MUCOSAL CYTOKINE PROFILE IN ULCERATIVE COLITIS PATIENTS UNDER CONVENTIONAL AND ANTI-TNF-A TREATMENT

Antonio Gasbarrini  et al.

Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report

Antonio Gasbarrini  et al.

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Antonio Gasbarrini  et al.

SIXTH-LINE ERADICATION THERAPY AGAINST HELICOBACTER PYLORI INFECTION: PRELIMINARY DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
SIXTH-LINE ERADICATION THERAPY AGAINST HELICOBACTER PYLORI INFECTION: PRELIMINARY DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Antonio Gasbarrini  et al.

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Antonio Gasbarrini  et al.

SARCOPENIA AND IBD: MOLECULAR AND MICROBIAL PATHWAYS AND POTENTIAL PHARMACOLOGICAL MODULATORS IN EXPERIMENTAL MODELS OF CHRONIC INFLAMMATORY BOWEL DISEASE
SARCOPENIA AND IBD: MOLECULAR AND MICROBIAL PATHWAYS AND POTENTIAL PHARMACOLOGICAL MODULATORS IN EXPERIMENTAL MODELS OF CHRONIC INFLAMMATORY BOWEL DISEASE

Antonio Gasbarrini  et al.

PREVALENCE AND CHARACTERISTICS OF GASTROINTESTINAL SYMPTOMS IN A LARGE WESTERN COHORT OF PATIENTS WITH CORONAVIRUS DISEASE 2019: A PROSPECTIVE OBSERVATIONAL STUDY
PREVALENCE AND CHARACTERISTICS OF GASTROINTESTINAL SYMPTOMS IN A LARGE WESTERN COHORT OF PATIENTS WITH CORONAVIRUS DISEASE 2019: A PROSPECTIVE OBSERVATIONAL STUDY

Antonio Gasbarrini  et al.

EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Antonio Gasbarrini  et al.

FREE LIGHT CHAINS: NEW POTENTIAL BIOMARKERS FOR DISEASE STRATIFICATION IN NON-ALCOHOLIC FATTY LIVER DISEASE
FREE LIGHT CHAINS: NEW POTENTIAL BIOMARKERS FOR DISEASE STRATIFICATION IN NON-ALCOHOLIC FATTY LIVER DISEASE

Antonio Gasbarrini  et al.

Item 1 - 20 / 85
1
2 3 4 5